CAJ | 학술논문

免疫抑制剂目前仍然是自身免疫病和移植排斥反应的主要治疗方法,但是它能非特异性地抑制患者对肿瘤和感染的抵抗能力.选择性清除抗原表位特异性T细胞理论上能减缓T细胞介导的病理作用,同时能保留机体的整体免疫功能状态.近年来,MHC四聚体技术和杀伤性人工抗原递呈细胞技术被用来靶向清除抗原特异性T细胞,以pMHC复合体为靶向分子,特异性结合表位特异性T细胞,同时利用放射性同位素、毒性蛋白或负调节分子等杀伤T细胞.体外实验和动物体内实验的良好结果预示着这些技术在自身免疫病、变态反应、T细胞肿瘤和移植排斥反应的治疗中有着潜在的应用前景.
면역억제제목전잉연시자신면역병화이식배척반응적주요치료방법,단시타능비특이성지억제환자대종류화감염적저항능력.선택성청제항원표위특이성T세포이론상능감완T세포개도적병리작용,동시능보류궤체적정체면역공능상태.근년래,MHC사취체기술화살상성인공항원체정세포기술피용래파향청제항원특이성T세포,이pMHC복합체위파향분자,특이성결합표위특이성T세포,동시이용방사성동위소、독성단백혹부조절분자등살상T세포.체외실험화동물체내실험적량호결과예시착저사기술재자신면역병、변태반응、T세포종류화이식배척반응적치료중유착잠재적응용전경.
lmmunosuppressive drugs dominate the current therapeutic landscape of autoimmune disorders and graft rejection.However,non-specific immune-ablation treatments compromise the ability of the host to respond to tumor and infection,whereas the selective removal of antigen-specific T cells could theoretically ameliorate T-cell-mediated pathology and preserve the rest of the host immune function.During recent years,major histocompatibility complex(MHC)tetramers and killer artificial antigen-presenting cells have been used to deplete antigen-specific T cells.Epitope-specific T cells are targeted by MHC/peptide complexes,followed by killing with radioisotope,toxin orinhibitory molecules.The promising results obtained in vitro and in animal models demonstrated their therapeutic potency for the treatment of autoimmune diseases,allergic diseases,Tcell malignancies and graft rejection.